



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

22 March 2018
EMA/CHMP/175713/2018
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Cabometyx cabozantinib

On 22 March 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Cabometyx. The marketing authorisation holder for this medicinal product is Ipsen Pharma.

The CHMP adopted an extension to the existing indication as follows²:

“Cabometyx is indicated for the treatment of advanced renal cell carcinoma (RCC):

- **in treatment-naïve adults with intermediate or poor risk (see section 5.1)**
- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.”

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² **New text in bold**

